A high priority, I agree, but not as high as commercialising the products in the BTM lineage.
I’m happy for R&D activities in the hernia etc. space to be prioritised but funding the next steps with those products should not detract from the global rollout of BTM, MTX, and SynPath.
But I trust management and board to be better equipped than anyone here, including me, to get the timing and allocation of resources right.
There is so much to be looking forward to over the next few years.
A high priority, I agree, but not as high as commercialising the...
-
- There are more pages in this discussion • 451 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.45 |
Change
0.010(0.41%) |
Mkt cap ! $1.691B | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.51 | $2.43 | $5.243M | 2.122M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 35541 | $2.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.46 | 2681 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |